🇺🇸 FDA
Patent

US 11365394

Enhanced immune effector cells and use thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11365394 (Enhanced immune effector cells and use thereof) held by Fate Therapeutics, Inc. expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K35/545, A61K38/00